Bourgeon Capital Management LLC Acquires 5,495 Shares of Johnson & Johnson (NYSE:JNJ)

Posted by on Apr 3rd, 2023

Bourgeon Capital Management LLC raised its holdings in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 95.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 11,245 shares of the company’s stock after acquiring an additional 5,495 shares during the quarter. Bourgeon Capital Management LLC’s holdings in Johnson & Johnson were worth $1,986,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also bought and sold shares of the company. Glassy Mountain Advisors Inc. purchased a new stake in shares of Johnson & Johnson in the fourth quarter worth $35,000. Retirement Financial Solutions LLC purchased a new stake in shares of Johnson & Johnson in the fourth quarter worth $40,000. TD Capital Management LLC purchased a new stake in shares of Johnson & Johnson in the third quarter worth $48,000. Iron Horse Wealth Management LLC raised its position in shares of Johnson & Johnson by 112.8% in the fourth quarter. Iron Horse Wealth Management LLC now owns 300 shares of the company’s stock worth $53,000 after buying an additional 159 shares in the last quarter. Finally, Piershale Financial Group Inc. purchased a new stake in shares of Johnson & Johnson in the fourth quarter worth $61,000. Institutional investors own 67.94% of the company’s stock.

Johnson & Johnson Stock Up 1.0 %

Shares of NYSE:JNJ opened at $155.00 on Monday. The company has a current ratio of 0.99, a quick ratio of 0.77 and a debt-to-equity ratio of 0.35. The stock has a market capitalization of $403.66 billion, a P/E ratio of 23.00, a price-to-earnings-growth ratio of 2.64 and a beta of 0.54. Johnson & Johnson has a 12-month low of $150.11 and a 12-month high of $186.69. The stock’s 50-day moving average price is $158.02 and its 200-day moving average price is $167.18.

Johnson & Johnson (NYSE:JNJ – Get Rating) last posted its earnings results on Tuesday, January 24th. The company reported $2.35 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.22 by $0.13. The company had revenue of $23.71 billion for the quarter, compared to analysts’ expectations of $23.90 billion. Johnson & Johnson had a return on equity of 35.76% and a net margin of 18.90%. Johnson & Johnson’s quarterly revenue was down 4.4% on a year-over-year basis. During the same period last year, the firm earned $2.13 earnings per share. On average, equities analysts anticipate that Johnson & Johnson will post 10.5 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, March 7th. Investors of record on Tuesday, February 21st were paid a $1.13 dividend. The ex-dividend date was Friday, February 17th. This represents a $4.52 annualized dividend and a dividend yield of 2.92%. Johnson & Johnson’s payout ratio is presently 67.06%.

Analyst Ratings Changes

A number of research firms have weighed in on JNJ. Morgan Stanley raised their price target on Johnson & Johnson from $176.00 to $180.00 and gave the company an “equal weight” rating in a research report on Wednesday, January 25th. Piper Sandler lowered their price target on Johnson & Johnson from $55.00 to $52.00 in a research report on Monday, February 6th. Guggenheim began coverage on Johnson & Johnson in a research report on Tuesday, February 28th. They set a “neutral” rating and a $161.00 price target on the stock. StockNews.com began coverage on Johnson & Johnson in a research report on Thursday, March 16th. They set a “strong-buy” rating on the stock. Finally, Atlantic Securities raised their price target on Johnson & Johnson from $160.00 to $168.00 and gave the company a “neutral” rating in a research report on Wednesday, January 25th. Eight research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $173.67.

Insider Buying and Selling

In related news, insider James D. Swanson sold 1,062 shares of the firm’s stock in a transaction dated Monday, March 6th. The stock was sold at an average price of $154.66, for a total value of $164,248.92. Following the sale, the insider now directly owns 9,215 shares of the company’s stock, valued at $1,425,191.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.35% of the stock is owned by insiders.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.

Featured Articles

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.